iShares Trust. Holdings as of Jul 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency SharesCash or money market | 10.39% | $19.83M | 19,834,626 |
| Bayer Aktiengesellschaft | 4.81% | $10.59M | 165,508 |
| GSK PLC | 3.63% | $9.35M | 266,670 |
| Twist Bioscience CorpTWST | 4.79% | $9.15M | 99,937 |
| Roche Holding AG | 3.85% | $9.08M | 16,796 |
| REVOLUTION MEDICINES, INC.RVMD | 4.55% | $8.69M | 46,352 |
| IPSEN SA | 3.84% | $8.45M | 37,928 |
| REGENERON PHARMACEUTICALS, INC.REGN | 4.35% | $8.30M | 10,887 |
| INCYTE CORPORATIONINCY | 4.23% | $8.08M | 67,570 |
| MODERNA, INC.MRNA | 4.19% | $7.99M | 145,819 |
| SANOFI SA | 3.46% | $7.63M | 76,788 |
| MERCK & CO., INC.MRK | 3.91% | $7.46M | 57,270 |
| VERTEX PHARMACEUTICALS INCORPORATEDVRTX | 3.87% | $7.39M | 15,481 |
| BioNTech SEBNTX, Other | 3.73% | $7.11M | 78,540 |
| EXELIXIS, INC.EXEL | 3.65% | $6.96M | 131,275 |
| IDEAYA Biosciences IncIDYA | 3.36% | $6.41M | 180,483 |
| Immunitybio IncIBRX | 3.07% | $5.86M | 817,183 |
| ARCUS BIOSCIENCES, INC.RCUS | 2.68% | $5.12M | 181,763 |
| CARIS LIFE SCIENCES, INC.CAI | 2.18% | $4.17M | 266,135 |
| Iovance Biotherapeutics IncIOVA | 1.80% | $3.43M | 841,830 |
| NUVATION BIO INC.NUVB | 1.78% | $3.39M | 536,281 |
| CRISPR Therapeutics AG | 1.57% | $2.99M | 62,247 |
| ABCELLERA BIOLOGICS INC.ABCL | 1.52% | $2.91M | 508,935 |
| Vir Biotechnology IncVIR | 1.31% | $2.51M | 289,265 |
| NOVAVAX, INC.NVAX | 1.30% | $2.49M | 339,643 |
| Janux Therapeutics IncJANX | 0.99% | $1.88M | 124,166 |
| Corvus Pharmaceuticals IncCRVS | 0.95% | $1.82M | 137,099 |
| Personalis IncPSNL | 0.89% | $1.70M | 134,479 |
| Kura Oncology IncKURA | 0.88% | $1.68M | 186,448 |
| RIGEL PHARMACEUTICALS, INC.RIGL | 0.75% | $1.43M | 38,807 |
| GENMAB A/S | 4.23% | $1.25M | 28,069 |
| CytomX Therapeutics IncCTMX | 0.61% | $1.17M | 375,908 |
| VERASTEM, INC.VSTM | 0.54% | $1.04M | 178,719 |
| Alvotech SA | 0.53% | $1.01M | 244,900 |
| VALNEVA SE | 0.45% | $999.01K | 349,239 |
| Design Therapeutics IncDSGN | 0.52% | $996.42K | 81,808 |
| Xencor IncXNCR | 0.52% | $983.64K | 48,671 |
| INTELLIA THERAPEUTICS, INC.NTLA | 0.51% | $981.36K | 91,888 |
| OCUGEN, INC.OCGN | 0.47% | $890.25K | 723,783 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB | 0.46% | $870.87K | 622,048 |
| Ginkgo Bioworks Holdings IncDNA | 0.43% | $819.71K | 101,324 |
| Sunshine Lake Pharma Co Ltd | 0.98% | $239.01K | 351,500 |
| Prime Medicine, IncPRME | 0.10% | $191.20K | 65,480 |
| GenFleet Therapeutics (Shanghai) Inc | 0.78% | $188.83K | 419,200 |
| BlackRock Funds III: BlackRock Cash Funds: Treasury; SL Agency SharesCash or money market | 0.09% | $177.86K | 177,863 |
| Shanghai Henlius Biotech Inc | 0.51% | $122.94K | 135,900 |
| GREAT BRITISH POUNDOther | 0.03% | $78.64K | 43,296 |
| Takeda Pharmaceutical Company Limited | 4.05% | $48.58K | 225,100 |
| XAV HEALTH CARE SEP26Derivative | 0.01% | $25.69K | 3 |
| ONO PHARMACEUTICAL CO., LTD. | 1.91% | $22.97K | 244,500 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.